Back to results
US 11,060,152 B2Granted
Methods for the surveillance, diagnosis and screening of bladder cancer
AssigneeOncodiag
InventorJean-Pierre Roperch
Life of this patent
Estimating the term…
Abstract
A method of diagnosing or predicting a bladder cancer, or a risk of a developing a bladder cancer in a subject is provided, which method includes the detection of specific mutations in the FGFR3 gene in a first biological sample; and the measure of the degree of methylation of target genes in a biological sample obtained from the subject in a second biological sample.
Claims6
A method for the treatment of non-muscle invasive bladder cancer, wherein said method comprises the steps of:
- a) analyzing, in a biological sample obtained from a subject, mutations at 742C→T, 746→G, 1114G→T, and 1124A→G by reference to the nucleotide numbers of SEQ ID NO:
- 1;
- or Arg248Cys, Ser249Cys, Gly372Cys, and Tyr375Cys, by reference to the amino acid numbers of SEQ ID NO:
- 2, in the FGFR3 gene;
- b) measuring, in the biological sample, the degree of methylation of SEPTIN 9 and HS3ST2,
- c) detecting at least one mutation among 742C→T, 746C→G, 1114G→T, and 1124A→G, and hypermethylation of SEPTIN 9 and HS3ST2;
- d) identifying the subject having non-muscle invasive bladder cancer;
- and
- e) treating the subject having the non-muscle invasive bladder cancer with a bladder cancer treatment.
6 more elements
Dependencies are inferred from the claim text.